Genomictree, Inc.

As of June 30, 2026, Genomictree, Inc. carries a market capitalization of 271.75B, placing it among publicly traded companies globally. Its enterprise value stands at 192.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genomictree, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Genomictree, Inc. has 24.53M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 90.58, and the price-to-book ratio stands at 2.23.

These figures are as of June 30, 2026. The EV/Sales ratio of 65.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 192.90B versus a market cap of 271.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Genomictree, Inc. maintains a current ratio of 60.85, meaning it holds 60.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of -42.28 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Genomictree, Inc. posted a negative return on equity (ROE) of -7.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.28, reflecting losses generated across the asset base. The company generates approximately 38.39M in revenue per employee across its workforce of 76.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.00 indicates how many times Genomictree, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Genomictree, Inc. recorded 1.19M in income tax expense. The company reported a pretax loss of -9.18B and -9.03B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Genomictree, Inc.'s stock has declined approximately 50.63% over the past 52 weeks. The 50-day moving average sits at 11,208.20, while the 200-day moving average is 15,911.60.

Over the twelve months ended June 30, 2026, Genomictree, Inc. generated 2.95B in revenue and converted that into -9.03B in net income, yielding earnings per share of -381.71. EBITDA reached -10.55B, while operating income came in at -11.74B.

As of June 30, 2026, Genomictree, Inc. holds 79.18B in cash and equivalents against 43.98M in total debt, resulting in a net debt position of -17.47B. Total book value stands at 121.64B, with working capital of 79.83B providing operational flexibility.

Genomictree, Inc. produced -10.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.99B in capital expenditures, free cash flow totaled -12.53B - equivalent to -520.37 per share.

Over the twelve months ended June 30, 2026, Genomictree, Inc. posted a gross margin of -5.02, reflecting its pricing power and cost economics. The operating margin of -398.40 and net profit margin of -306.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.70: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.03, meaning Genomictree, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genomictree, Inc.'s most recent stock split took place on September 14, 2018 with a 1:2 split ratio.

As of June 30, 2026, Genomictree, Inc. has an Altman Z-Score of 66.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.